Chongqing Pharmaceutical Research Institute Co., LTD

Chongqing Pharmaceutical Research Institute Co., Ltd. (CPRI) is an R&D-based & client-oriented enterprise engaged in: Pharmaceutical R&D Early stage process development cGMP manufacturing of APIs & advanced intermediates Founded in 1950s, formerly known as the state-owned Chongqing Pharmaceutical Research Institute, CPRI was one of the pioneers involved in drug R&D and cGMP-compliant API manufacturing in China. In 2001, CPRI became a subsidiary of FOSUN Pharmaceutical (Group), Co, Ltd, which is a leading pharmaceutical company in China. With decades of experience in drug R&D in China, CPRI has successfully completed over 200 research projects for our customers in recent 20 years. And we have filed for 48 Chinese patents or PCTs, 8 patents have been granted. Taking advantage of the fully integrated drug R&D system, CPRI is ready to offer R&D services to pharmaceutical companies from home and abroad, including diversified contract research services for API development. Moreover, we provide high-quality APIs such as Pemetrexed Disodium (for R&D use), Iron Sucrose, etc, manufactured in cGMP-compliant workshops.